JP2012522840A5 - - Google Patents

Download PDF

Info

Publication number
JP2012522840A5
JP2012522840A5 JP2012504771A JP2012504771A JP2012522840A5 JP 2012522840 A5 JP2012522840 A5 JP 2012522840A5 JP 2012504771 A JP2012504771 A JP 2012504771A JP 2012504771 A JP2012504771 A JP 2012504771A JP 2012522840 A5 JP2012522840 A5 JP 2012522840A5
Authority
JP
Japan
Prior art keywords
ester
pharmaceutically acceptable
acceptable salt
alkenyl
alkyl ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012504771A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012522840A (ja
JP5687687B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/030073 external-priority patent/WO2010118006A1/en
Publication of JP2012522840A publication Critical patent/JP2012522840A/ja
Publication of JP2012522840A5 publication Critical patent/JP2012522840A5/ja
Application granted granted Critical
Publication of JP5687687B2 publication Critical patent/JP5687687B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012504771A 2009-04-06 2010-04-06 癌を治療するための(2’−デオキシ−リボフラノシル)−1,3,4,7−テトラヒドロ−(1,3)ジアゼピン−2−オン誘導体 Active JP5687687B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16711209P 2009-04-06 2009-04-06
US61/167,112 2009-04-06
PCT/US2010/030073 WO2010118006A1 (en) 2009-04-06 2010-04-06 (2 ' -deoxy-ribofuranosyl) -1,3,4, 7-tetrahydro- (1,3) iazepin-2-0ne derivatives for treating cancer

Publications (3)

Publication Number Publication Date
JP2012522840A JP2012522840A (ja) 2012-09-27
JP2012522840A5 true JP2012522840A5 (https=) 2013-05-23
JP5687687B2 JP5687687B2 (ja) 2015-03-18

Family

ID=42126083

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012504771A Active JP5687687B2 (ja) 2009-04-06 2010-04-06 癌を治療するための(2’−デオキシ−リボフラノシル)−1,3,4,7−テトラヒドロ−(1,3)ジアゼピン−2−オン誘導体

Country Status (10)

Country Link
US (1) US8324180B2 (https=)
EP (1) EP2417146B1 (https=)
JP (1) JP5687687B2 (https=)
AR (1) AR076262A1 (https=)
AU (2) AU2010234637B2 (https=)
CA (1) CA2757743C (https=)
ES (1) ES2593088T3 (https=)
JO (1) JO3197B1 (https=)
TW (1) TWI477508B (https=)
WO (1) WO2010118006A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
UY32546A (es) * 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer
AU2010234562B2 (en) * 2009-04-06 2016-05-12 Taiho Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
KR102385603B1 (ko) * 2013-08-19 2022-04-11 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) * 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4275057A (en) * 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
EP0160079B1 (en) 1983-10-26 1990-01-31 GREER, Sheldon B. Method and materials for sensitizing neoplastic tissue to radiation
ATE92499T1 (de) * 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
FR2682112B1 (fr) * 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5594124A (en) * 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5606048A (en) * 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5426183A (en) * 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5371210A (en) * 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en) * 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
WO1994019362A1 (en) * 1993-02-23 1994-09-01 City Of Hope 4-ethoxy 5-fluoro 2'deoxyuridine
WO1994026761A1 (en) 1993-05-14 1994-11-24 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) * 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) * 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
TW466112B (en) 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
CA2342981A1 (en) 1998-09-25 2000-04-06 Warner-Lambert Company Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
US6933287B1 (en) * 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
ATE339960T1 (de) 1999-03-01 2006-10-15 Halogenetics Inc Verwendung von zusammensetzungen enthaltend cldc als strahlungssensibilisatoren in der behandlung von neoplastischen erkrankungen
US6462191B1 (en) * 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
DE60144573D1 (de) 2000-11-29 2011-06-16 Mitsui Chemicals Inc Verfahren und Zwischenprodukte bei der Synthese von L-Thymidin
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
EP1387850A2 (en) 2001-05-18 2004-02-11 Rakesh Kumar Antiviral nucleosides
AU2003278904A1 (en) 2002-09-24 2004-04-19 Kornis Pharmaceuticals, Incorporated 1, 3, 5-triazines for treatment of viral diseases
US8158770B2 (en) * 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
WO2006015346A1 (en) 2004-07-30 2006-02-09 Pharmaessentia Corp. STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
WO2006063105A1 (en) 2004-12-08 2006-06-15 Sicor Inc. Difluoronucleosides and process for preparation thereof
US20080080200A1 (en) 2006-09-29 2008-04-03 Grote Industries, Inc Lighting systems using light active sheet material with integrated leadframe, and methods for manufacturing the same
WO2008085611A2 (en) * 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
UY32546A (es) * 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer
AU2010234562B2 (en) * 2009-04-06 2016-05-12 Taiho Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2011518833A5 (https=)
JP2010536766A5 (https=)
JP2013032389A5 (https=)
JP2012092103A5 (https=)
JP2010501534A5 (https=)
JP2013532130A5 (https=)
JP2009535462A5 (https=)
JP2014500861A5 (https=)
EP4328223A3 (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
JP2009149903A5 (https=)
JP2016510323A5 (https=)
JP2013507423A5 (https=)
JP2013518107A5 (https=)
JP2013528182A5 (https=)
JP2009545527A5 (https=)
JP2007522220A5 (https=)
JP2007269812A5 (https=)
EA201201377A1 (ru) Определенные аминопиридазины, композиции на их основе и способы их использования
JP2011527299A5 (https=)
JP2013515822A5 (https=)
EP2682387A3 (en) C7-fluoro substituted tetracycline compounds
JP2013515006A5 (https=)
JP2007302689A5 (https=)
JP2010530373A5 (https=)
JP2011510079A5 (https=)